Pharmaceuticals News and Research

RSS

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication Repatha (evolocumab) Injection, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to be approved in Japan.

22 Jan 2016

Swedish research group publishes scientific discoveries concerning EKC in Acta Ophthalmologica journal

A Swedish research group at St. Erik Eye Hospital, Stockholm, Karolinska Institutet, Solna, and Umeå University has published scientific discoveries concerning the serious infectious eye disease EKC in the prestigious journal Acta Ophthalmologica.

22 Jan 2016

Oxeia accelerating development of neurometabolic treatments for concussions

Oxeia Biopharmaceuticals, Inc., a biotechnology company, is catalyzing the development of first-in-class neurometabolic treatments for concussions and other aspects of brain injury.

21 Jan 2016

FDA approves Allergan's sNDA to update label for DALVANCE (dalbavancin) for injection

Allergan plc, a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration has approved the company's supplemental new drug application (sNDA) to update the label for DALVANCE (dalbavancin) for injection.

21 Jan 2016

MD Anderson and AbbVie join forces to design new immunotherapy cancer patients

The immunotherapy platform at The University of Texas MD Anderson Cancer Center and the global biopharmaceutical company AbbVie will join forces to find new ways to unleash the immune system's potential to fight cancer.

21 Jan 2016

Abingworth announces closing of $105m clinical co-development fund

Abingworth, the international investment group dedicated to life sciences, today announced the closing of the $105m Abingworth Clinical Co-Development Fund (ACCF), its 11th life sciences fund. ACCF was oversubscribed, exceeding its target of $100 million, and will co-invest with other Abingworth funds.

21 Jan 2016

Johnson & Johnson joins industry-wide call to address growing problem of antimicrobial resistance

Johnson & Johnson today announced it has joined more than 80 companies and organizations in signing the Declaration on Combating Antimicrobial Resistance (AMR), an industry-wide call to action announced at the World Economic Forum in Davos, Switzerland.

21 Jan 2016

CSU's BioMARC awarded DoD contract to help develop new vaccines to combat encephalitic viruses

Colorado State University's Biopharmaceutical Manufacturing and Academic Resource Center has been awarded a 10-month, $4.6 million contract funded by the Department of Defense to help develop and manufacture new vaccines to fight encephalitic viruses that cause inflammation of the brain.

21 Jan 2016

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

OncoGenex Pharmaceuticals, Inc. announced today that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit.

20 Jan 2016

Upsher-Smith, Saniona sign drug discovery and development agreement

Upsher-Smith Laboratories, Inc., through its wholly-owned subsidiary Proximagen Ltd., and Saniona, a leading biotech company in the field of ion channels, today announce that they have entered into a drug discovery and development collaboration.

20 Jan 2016

Age plays key role when it comes to patients' access to most efficient psoriasis treatment

A new study from Umeå University in Sweden shows that age plays a huge role when it comes to patients' access to psoriasis treatment. Researchers who have examined if patients of varying ages have the same access to the most efficient psoriasis treatment, found that an age increase of 30 years resulted in an average 65 per cent reduction in likelihood of obtaining treatment with biologics.

20 Jan 2016

New Georgia Tech research center launched to manufacture living cells for cell-based therapies

A $15.7 million grant from the Atlanta-based Marcus Foundation has helped launch a new Georgia Institute of Technology research center that will develop processes and techniques for ensuring the consistent, low-cost, large-scale manufacture of high-quality living cells used in cell-based therapies.

20 Jan 2016

Four USF professors selected as AIMBE College of Fellows

Four University of South Florida professors have been elected to the 2016 College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE): Cesario Borlongan and Shyam Mohapatra from the USF Morsani College of Medicine, USF Health; and Robert Frisina, Jr., and Sudeep Sarkar from the USF College of Engineering.

20 Jan 2016

Rapastinel demonstrates pro-cognitive benefits in animal model of cognitive impairment

Allergan plc, a leading global pharmaceutical company, announced today that new data on the investigational medication rapastinel (GLYX-13) and its lack of impairment on cognitive function were published in the peer-reviewed journal Behavioural Brain Research.

19 Jan 2016

CASI Pharmaceuticals receives $10.3 million in strategic financing

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announces it has received approximately $10.3 million in a strategic financing previously announced on September 21, 2015.

19 Jan 2016

CRISPR/Cas9 gene editing technique could be controlled using RNA-based drugs

In just the past few years, researchers have found a way to use a naturally occurring bacterial system known as CRISPR/Cas9 to inactivate or correct specific genes in any organism. CRISPR/Cas9 gene editing activity runs continuously, though, leading to risk of additional editing at unwanted sites.

19 Jan 2016

New blood biomarkers could lead to better evaluation of treatment for patients with PAH

New blood biomarkers reflecting vasoreactivity in lung blood vessels of patients with heart- and lung disease, can lead to simplified diagnostics and better evaluation of treatment for patients with the condition pulmonary arterial hypertension (PAH).

18 Jan 2016

NSCLC treatments market in Europe expected to cross US$ 3 billion by 2019

According to recently published Pharmaion report, "Europe Non-Small Cell Lung Cancer Treatments Market Opportunities, 2010 - 2020", the non-small cell lung cancer (NSCLC) treatments market in Europe is anticipated to cross US$ 3 billion by 2019.

18 Jan 2016

UM SOM selected to work with BARDA to develop radiologic and nuclear countermeasures

University of Maryland School of Medicine Department of Radiation Oncology Chair and Professor William F. Regine, MD, FACR, FACRO, and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that researchers at the UM SOM have been selected as key contractors by the Biomedical Advanced Research and Development Authority, for its Radiation Nuclear Animal Model Development program.

18 Jan 2016

TSRI researchers develop new technique for modifying complex drug molecules

Chemists at The Scripps Research Institute have developed a versatile new technique for making modifications—especially one type of extremely difficult, but much-sought-after modification—to complex drug molecules.

18 Jan 2016

Pharmaceuticals News and Research

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Swedish research group publishes scientific discoveries concerning EKC in Acta Ophthalmologica journal

Oxeia accelerating development of neurometabolic treatments for concussions

FDA approves Allergan's sNDA to update label for DALVANCE (dalbavancin) for injection

MD Anderson and AbbVie join forces to design new immunotherapy cancer patients

Abingworth announces closing of $105m clinical co-development fund

Johnson & Johnson joins industry-wide call to address growing problem of antimicrobial resistance

CSU's BioMARC awarded DoD contract to help develop new vaccines to combat encephalitic viruses

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

Upsher-Smith, Saniona sign drug discovery and development agreement

Age plays key role when it comes to patients' access to most efficient psoriasis treatment

New Georgia Tech research center launched to manufacture living cells for cell-based therapies

Four USF professors selected as AIMBE College of Fellows

Rapastinel demonstrates pro-cognitive benefits in animal model of cognitive impairment

CASI Pharmaceuticals receives $10.3 million in strategic financing

CRISPR/Cas9 gene editing technique could be controlled using RNA-based drugs

New blood biomarkers could lead to better evaluation of treatment for patients with PAH

NSCLC treatments market in Europe expected to cross US$ 3 billion by 2019

UM SOM selected to work with BARDA to develop radiologic and nuclear countermeasures

TSRI researchers develop new technique for modifying complex drug molecules

Event guide: World ADC Asia eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring